Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

M. N. Zamotaeva; V. I. Inchina; V. V. Konorev; Yu. V. Kuznetsov; N. D. Kuz’michev

doi:10.1007/s10517-018-4166-y

Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

Авторлар: Zamotaeva M.¹, Inchina V.¹, Konorev V.¹, Kuznetsov Y.², Kuz’michev N.¹
Мекемелер:
1. N. P. Ogarev Mordovian National Research State University
2. N. M. Emanuel Institute of Biochemical Physics
Шығарылым: Том 165, № 3 (2018)
Беттер: 344-346
Бөлім: Article
URL: https://journals.rcsi.science/0007-4888/article/view/240286
DOI: https://doi.org/10.1007/s10517-018-4166-y
ID: 240286

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Статистика

Аннотация

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.